XB-2202

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameXB-2202
Drug Alias NamePDGF Receptor Beta Targeted mAb (X-Body)antibody program (X-BODY / Jiangsu Hengrui)platelet-derived growth factor receptor beta-targeted monoclonal antibody (X-BODY)mAb program (X-BODY / Jiangsu Hengrui)PDGFRB-targeted mAb (X-BODY) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsAngiogenesis inhibitorsAnticancer protein kinase inhibitors +[5] 
TargetsNerve growth factor receptor Trk-APlatelet-derived growth factor receptor beta
Therapy Area/IndicationsMacular DegenerationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMacau +[5] 
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesX-BODY BioSciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesX-BODY BioSciencesJuno Therapeutics IncJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsMacular DegenerationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A